Biologic Therapies Summit XI Webcast Series, repurposed from the 2025 Biologic Therapies Summit XI, is designed for healthcare professionals seeking to deepen their understanding of cutting-edge treatments for immune-mediated inflammatory diseases.
Webcasts
Release date: July 10, 2025
Expiration date: July 9, 2027
Estimated Time: 2 hours and 45 minutes
Type: Webcast
Technical Requirements: None
Specialty: rheumatology, allergy/immunology, dermatology, internal medicine, nursing
Emerging Treatments in iMIDS
Faculty: Rohit Aggarwal, MD, MS;
Jack Cush, MD;
Michelle Petri, MD, MPH;
Michael Putman, MD, MSci;
Christopher Ritchlin, MD, MPH
Release date: July 10, 2025
Expiration date: July 9, 2027
Estimated Time: 2 hours and 45 minutes
Type: Webcast
Technical Requirements: None
Specialty: rheumatology, allergy/immunology, dermatology, internal medicine, nursing
Release date: July 10, 2025
Expiration date: July 9, 2027
Estimated Time: 1 hour and 45 minutes
Type: Webcast
Technical Requirements: None
Specialty: rheumatology, allergy/immunology, dermatology, internal medicine, nursing
Series Learning Objectives
- Critically appraise and integrate clinical data on the efficacy and toxicity of CAR T-cell therapies, cellular therapies, and other advanced treatments, with the objective of identifying and proposing strategies that could lead to long-term remission or cure of immune-mediated inflammatory diseases.
- Investigate and differentiate between infectious complications from biologic therapies and immune-related adverse events associated with checkpoint inhibitor therapies, while formulating effective prevention and management strategies.
- Examine the mechanism of action of Janus kinase (JAK) inhibitors in modulating immune responses, and identify the potential toxicities and adverse effects, particularly infection risks, to ensure the optimal administration of JAK inhibitors in patients.
- Evaluate the efficacy and safety of IL-17 inhibitors (e.g., secukinumab, ixekizumab) and IL-23 inhibitors (e.g., ustekinumab, guselkumab) in treating immune mediated inflammatory diseases, and assess the risks, including susceptibility to infections and the implications of long-term use.
- Explore and interpret the latest advances in IL-23 inhibitors for immune mediated inflammatory diseases, and assess their potential for treating other inflammatory conditions by examining emerging research and future clinical applications.
- Critically evaluate emerging therapeutic strategies for difficult-to-treat psoriatic arthritis (PsA), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory myopathies, and propose innovative approaches to optimize patient outcomes based on current advancements.
Target Audience
The online series is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in the treatment of vasculitis.
Acknowledgment
The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from:
AstraZeneca Pharmaceuticals
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Department of Rheumatic & Immunologic Diseases, and Cleveland Clinic’s RJ Fasenmyer Center for Clinical Immunology.
